Kura Oncology (NASDAQ:KURA) Insider Sells $224,462.58 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Francis Burrows sold 20,726 shares of the stock in a transaction that occurred on Thursday, September 24th. The stock was sold at an average price of $10.83, for a total transaction of $224,462.58. Following the transaction, the insider directly owned 42,327 shares in the company, valued at approximately $458,401.41. This represents a 32.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Kura Oncology Trading Down 0.9%

NASDAQ:KURA traded down $0.10 on Friday, hitting $10.76. 1,226,675 shares of the stock were exchanged, compared to its average volume of 1,672,906. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12. Kura Oncology, Inc. has a fifty-two week low of $7.36 and a fifty-two week high of $13.90. The stock has a market cap of $957.21 million, a PE ratio of -3.19 and a beta of 0.44. The stock has a fifty day moving average of $11.22 and a 200-day moving average of $10.13.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. As a group, equities analysts expect that Kura Oncology, Inc. will post -3.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $115,286,000. Armistice Capital LLC increased its stake in Kura Oncology by 5.7% in the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after purchasing an additional 264,000 shares in the last quarter. Bank of America Corp DE purchased a new stake in Kura Oncology during the second quarter valued at about $12,735,000. Dimensional Fund Advisors LP boosted its holdings in shares of Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after buying an additional 348,127 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Kura Oncology in the second quarter worth approximately $10,927,000.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a research report on Monday, August 24th. CLSA set a $24.00 price objective on Kura Oncology in a research note on Thursday, June 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Oppenheimer set a $24.00 price objective on Kura Oncology in a research report on Thursday, May 28th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.